Zobrazeno 1 - 10
of 44
pro vyhledávání: '"G. Milaki"'
Autor:
M. Perraki, Eleftheria-Kleio Dermitzaki, V. Georgoulias, Stella Apostolaki, F. Koinis, Ippokratis Messaritakis, Athanasios Kotsakis, Dora Hatzidaki, G. Milaki
Publikováno v:
Cancer Chemotherapy and Pharmacology. 80:101-108
The detection of circulating tumor cells (CTCs) is of prognostic significance in several tumor types. The present study evaluated the detection and the clinical relevance of CK19mRNA(+) CTCs in patients with advanced/metastatic non-small cell lung ca
Publikováno v:
Pathologica. 109(3)
The genetic profile is one of the major possible causes of spindle cell sarcoma. Irradiation has also been linked to this type of cancer. This means that if tissues have already been irradiated for other types of cancer, they can afterwards develop t
Autor:
Vassilis Georgoulias, Aris Polyzos, Nikolaos Kentepozidis, Stylianos Kakolyris, Nikolaos Ziras, Antonia Kalykaki, Nikolaos Androulakis, Nikolaos Vardakis, G. Milaki, Niki Karachaliou
Publikováno v:
Oncology. 78:356-360
Purpose: To evaluate the efficacy and tolerability of oxaliplatin (L-OHP) in combination with irinotecan (CPT-11) as first-line treatment of advanced biliary tract cancer. Patients and Methods: Patients with histologically confirmed nonresectable bil
Autor:
Charalambos Kouroussis, Nikos Androulakis, V. Georgoulias, Sophia Agelaki, S. Kakolyris, D. Mavroudis, John Souglakos, Nikolaos Xenidis, G. Milaki, Athanasios G. Pallis
Publikováno v:
Oncology. 69:384-390
Purpose: To evaluate the efficacy and tolerance of irinotecan (CPT-11) in combination with bolus and continuous infusion of 5-fluorouracil (5-FU) and leucovorin (LV) (FOLFIRI regimen) as first-line treatment of elderly patients with metastatic colore
Autor:
G. Milaki, Sofia Agelaki, Filippos Palamidas, Vassilis Georgoulias, Nikolaos Kentepozidis, Charalambos Kouroussis, Pavlos Papakotoulas, Kostas N. Syrigos, Lambros Vamvakas, Nikolaos Tzanakis, Aristidis Polyzos, M. Veslemes
Publikováno v:
Lung Cancer. 43:329-333
Purpose: To evaluate the efficacy and toxicity of the combination of gemcitabine and docetaxel in pretreated patients with small-cell lung cancer (SCLC). Patients and methods: Twenty-two pretreated patients (median age 61 years, PS: 0–1 in 77% and
Autor:
Sophia Agelaki, Athanasios Athanasiadis, Charalambos Kouroussis, Maltezakis G, Charalambos Christophylakis, G. Milaki, Varthalitis J, N. Vardakis, Georgoulias, Kostas N. Syrigos, Georgia Pavlakou, J. Boukovinas
Publikováno v:
Oncology. 66:192-196
Objective: To evaluate efficacy and toxicity of the combination of irinotecan and gemcitabine in pretreated patients having small-cell lung cancer. Patients andMethods: Thirty-one patients (median age 60 years, performance status 0–1 in 87% and 2 i
Autor:
Kostas Kalbakis, D. Mavroudis, Ch. Christophilakis, Ch. Kouroussis, N. Malamos, Nikos Androulakis, I. Varthalitis, V. Georgoulias, Aristidis Polyzos, G. Milaki
Publikováno v:
Oncology. 67:250-256
Objective: To evaluate the docetaxel-gemcitabine combination administered every 2 weeks in women with untreated metastatic breast cancer (MBC). Methods: Fifty-two patients with MBC received docetaxel 65 mg/m2 as front-line chemotherapy intravenously
Autor:
E, Saloustros, K, Kalbakis, N, Vardakis, A, Kalykaki, G, Milaki, M, Rovithi, S, Agelaki, Z, Saridaki, V, Georgoulias, D, Mavroudis
Publikováno v:
Journal of B.U.ON. : official journal of the Balkan Union of Oncology. 16(2)
Continuous administration of oral vinorelbine, given 3 times a week (metronomic), is feasible and exceptionally well tolerated at doses up to 50 mg with clinical activity against refractory tumors. In this phase II study oral metronomic vinorelbine a
Autor:
A. Matikas, Charalambos Kouroussis, Aris Polyzos, Nikolaos Kentepozidis, Vassilis Georgoulias, G. Milaki, Lambros Vamvakas, Athanasios Karampeazis, Charalambos Christophyllakis, Athanasios Kotsakis, D. Mavroudis, Sofia Agelaki
Publikováno v:
Journal of Geriatric Oncology. 5:S36-S37
Objective: To evaluate efficacy and toxicity of the combination of irinotecan and gemcitabine in pretreated patients having small-cell lung cancer. Patients and Methods: Thirty-one patients ( median age 60 years, performance status 0-1 in 87% and 2 i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::4fd04c85d7f7653ed6ed59a5d1196ece
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3085111
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3085111